Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Total Non-Current Liabilities (2018 - 2025)

Sangamo Therapeutics (SGMO) has 10 years of Total Non-Current Liabilities data on record, last reported at $81.4 million in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities rose 14.86% year-over-year to $81.4 million; the TTM value through Sep 2025 reached $81.4 million, up 14.86%, while the annual FY2024 figure was $77.9 million, 4.08% down from the prior year.
  • Total Non-Current Liabilities reached $81.4 million in Q3 2025 per SGMO's latest filing, up from $77.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $400.4 million in Q1 2021 and bottomed at $68.1 million in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $186.2 million, with a median of $90.2 million recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: soared 117.66% in 2021, then plummeted 70.56% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $345.4 million in 2021, then fell by 22.88% to $266.3 million in 2022, then tumbled by 69.5% to $81.2 million in 2023, then decreased by 4.08% to $77.9 million in 2024, then grew by 4.48% to $81.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $81.4 million in Q3 2025, $77.0 million in Q2 2025, and $80.3 million in Q1 2025.